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Abstract
Current pharmacological therapy for gastroparesis is limited by a few optional agents with high side effect profiles. Probiotics, which
exert both prokinetic and antibiotic properties, can be a good alternative. This study investigates the effects of capsules containing three
species of Lactobacillus on gastric emptying function by using a crossover placebo-controlled clinical trial. The 15 healthy participants
recruited were divided into two groups, with one group of 7 persons aged between 20-40 and another group of 8 persons aged between
41-60. All the participants in each group were provided with placebo capsules and probiotic capsules, respectively, to be taken twice a
day after meals for 3 weeks with crossover in the following 3 weeks. Tc-99m scintigraphy was performed at the beginning of weeks 0, 3
and 6 to determine the gastric emptying rate. All time-activity curves were constructed and the half time of gastric emptying (GEt1/2) was
calculated for the same subject for comparison. The GEt1/2 of the baseline, placebo and Lactobacillus regimen periods for the 20-40 age
group were 73.0 ± 16.0, 85.7 ± 10.5, and 87.8 ± 10.0 min, respectively, while those for the 41-60 age group were 79.1 ± 23.9, 70.9 ± 33.1,
and 68.4 ± 15.2 min, respectively. Comparison of the two groups showed a positive effect of probiotics capsules on the 41 to 60-year-old
participants (p = 0.013) but not on the 20 to 40-year-old participants. There was no significant statistical difference between the two groups
in the period of treatment with placebo. This early stage trial indicated that the multi-strain Lactobacillus capsule is safe and the results
provided some evidence that it accelerated gastric emptying in healthy adults above 40 years of age and may become a therapeutic approach
in future trials for pathological gastric emptying delay, by implication, especially in diabetic gastroparesis.
Key words: Lactobacillus, gastric emptying, gastroparesis, scintigraphy clinical trial

Introduction
Delayed or disordered gastric emptying has been associated with a variety of functional gastrointestinal disorders
and is considered a major pathophysiological mechanism
in the development of functional dyspepsia and gastroparesis(1-3). The prevalence of gastroparesis is not well-defined
in population-based studies(4), but it is assumed that up to
4% of the general population experiences symptoms of this
* Author for correspondence. Tel: +886-4-22840385 ext. 2208;
Fax: +886-4-2287-6211; E-mail: mylin@dragon.nchu.edu.tw

disorder(5,6). Therefore, the condition represents a significant
healthcare burden(7).
Physiological and molecular studies of the role of intestinal microbiota in maintaining normal GI function indicate
that colonisation with common commensals can indeed modify
the expression of a variety of genes involved in motility and
neurotransmission(8). The bidirectional interactions between
the gut microbiota and gastrointestinal physiology, so call the
“gut-brain axis” were recently concluded and reviewed(9,10).
Intestinal microflora participates in the development and
maintenance of gut sensory and motor functions by the
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release of bacterial substances and fermentation products,
and modulating intestinal neuroendocrine factors and the
effects of mediators released by the GI immune system(11).
For example, some studies demonstrated that mice infected
with H. pylori for 4 to 6 months developed delayed gastric
emptying, increased visceral perception and abnormal 24-h
feeding patterns(12-14).
Erythromycin, one of the macrolide antibiotics and
produced from a bacteria species Saccharopolyspora
erythraea(15), is widely accepted as a very potent pharmacological approach for gastroparesis. Many studies have shown
that erythromycin, administered either intravenously or
orally, is capable of accelerating gastric emptying in patients
with diabetic gastroparesis(1,16-18). The prokinetic effects are
partially attributed to agonist effects on neural and smooth
muscle motilin receptors, the physiologic regulators of fasting
gastroduodenal motility, evoking powerful, lumen-occluding
antral contractions(19,20). Another considerable effect of
erythromycin is its antibiotic property, which can influence
the balance of gut microbiota, thereby possibly contributing to
intestinal motility and gastric emptying. The promise of erythromycin-derived motilin receptor agonist (such as Mitemcinal)
(21-23)
raise an idea that other bacteria-derived substances can
exert therapeutic effects similar to erythromycin.
In contrast to antibiotics, probiotics are viable nonpathogenic bacteria that colonize the intestine, and therefore modify
the balance of the existing intestinal microflora and its metabolic activity, resulting in beneficial effects for the host(24,25).
The end-products of lactic acid bacteria fermentation (the
short-chain fatty acids [SCFAs], butyrate, acetate and propionate) may affect local and distant motor events(26,27). Immune
mediators are known to modulate various digestive functions,
many of which involve the enteric nervous system and smooth
muscles(28). The physiological mechanisms underlying these
effects involve changes in gastrointestinal motility, which is
improved in the upper and lower gut(11,29). Due to the production of diverse agents and various mechanisms, some specific
probiotics may be considered for the regimen of gastroparesis. Recent studies(11,29) suggest a useful role for L. reuteri
supplementation to accelerate gastric emptying in formulafed pre-term newborns.
The aim of the present study was to test the feasibility
of multiple strains of Lactobacillus for improving the gastric
emptying function. The currently available regimen for
gastroparesis, with a small number of prokinetic agents or
macrolide antibiotics, is limited by side effects. Probiotics
exert prokinetic and antimicrobiotic properties, and could
prove to be a good alternative option. A crossover, placebocontrolled clinical trial using Tc-99m scintigraphy was used
in this study.

Materials and Methods
I. Participants
Eligible volunteers were 2 male or 13 female, 20-60

years of age, and had no clinical evidence of any known illness
that can cause gastroparesis, including diabetes mellitus and
a previous diagnosis of functional dyspepsia. All had normal
gastric emptying function and no evidence of mechanical
gastric obstruction. Patients with GI symptoms, chronic
illness, pregnancy, antibiotic usage and health food usage
were not included in this study. Other exclusion criteria were
esophagitis, gastric atrophy or erosive gastroduodenal lesion
seen by panendoscopy, previous major abdominal surgery,
or GI obstruction seen on any imaging modality. Patients
with psychiatric disorders and those using non-steroidal antiinflammatory drugs (NSAIDs), steroids, or drugs influencing
gastric acid or gastric emptying function were also excluded.
Eligible participants filled out self-assessment questionnaires regarding their health status and personal information including body weight and height. Body Mass Index
(BMI) was calculated by dividing weight in kilograms by the
square of height in meters(30). All participants were grouped
according to two age ranges: 7 in the 20-40 year-old group
and 8 in the 41-60 year-old group.
II. Study Product
The commercial regimen consisted of capsules
containing multiple strains of Lactobacillus, including L.
paracasei 33, L. fermentum and L. acidophilius, approved
by the Food and Drug Administration, Department of Health,
Executive Yuan, R.O.C. The placebo capsules were identical
in appearance to the Lactobacillus capsules.
III. Study Design
This open label, placebo-controlled clinical trial was
conducted in accordance with the ethical principles that have
their origins in the Declaration of Helsinki, and was approved
by the Institutional Review Board (IRB) of Buddhist Dalin
Tzu Chi General Hospital in Taiwan (Registration No.
B09804025). All participants took placebo for 3 weeks,
followed by Lactobacillus capsules for another 3 weeks.
The daily regimen is taken twice, 30 min after breakfast
and dinner. The standardized scintigraphic image of gastric
emptying function was then obtained at screening, and at the
beginning of weeks 0, 3 and 6 (that is, at the beginning and
end of the placebo and Lactobacillus periods).
IV. Protocols of Scintigraphy
A solid phase gastric emptying scintigraphy was
performed as follows. The participants fasted for 8 h, registered for and received a basic physical examination and blood
tests, and then ingested a sandwich meal consisting of two
slices of toast and a microwaved egg. Two slices of toast
contain 300 calories, 7.7 g of protein, 8.4 g of fat, 48.5 g of
carbohydrate and 432 mg of sodium. The egg contains 60
calories, 7.6 g of protein, 3.3 g of fat and 290 mg of cholesterol, labeled with 1 mCi of Tc-99m sulphur colloid (Member
of IBA group-CIS France, Gif-sur-Yvette, France). After a
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Table 1. Subject characteristics
Healthy volunteers demographics and
baseline characteristics
Male, N (%)
Female, N (%)
Mean Age
BMI1
Blood glucose

Age 20-40

Age 41-60

0 (0)

2 (25)

7 (100)

6 (75)

32.4 (6.5)

44.1 (6.6)

21.2 (2.4)

24.1(3.7)

Before

After

Before

After

68.6(20.5)

100.1(7.0)

76.9(10.9)

93.9(10.7)

1

Values are means (SD).

meal with a cup of water (120 mL), the participants immediately underwent scintigraphic screening for 90 min, and
anterior and posterior dynamic images obtained using dual
gamma cameras. The radioactivity was measured continuously at 1 minute per frame and data were corrected for time
decay. For each time frame, the Region of interest (ROI) was
drawn around the image of the stomach and geometric mean
was calculated as the square root of the product of the counts
measured on the anterior and posterior images. Isotope
activity of the first frame at time 0 was taken as 100%. The
retention of isotope in ROI of each frame (1 min/frame) were
expressed by the % of maximum counts in the total stomach
as gastric emptying percentage (GEP). A simple linear fit was
applied to drive gastric emptying curve. Half-time of gastric
emptying (GEt1/2) was defined as the time to emptying of
50% of the gastric content initially measured at time 0. The
main parameters measured were percent gastric retention
at every 9 min at time 0, 9, 18, 27, 36, 45, 54, 63, 72, 81,
and 90 min as the conventional technique. All time-activity
curves were constructed and the half-time of gastric emptying
(GEt1/2) was calculated for the same subject for comparison.
V. Dosage and Safety
Tolerability was estimated by ADI (acceptable daily
intake) for probiotics and the NOAEL (no observed adverse
effect levels). From previously reported studies on animals,
Gratz et al. calculated the ADI for probiotics and the NOAEL
for human studies. These calculations suggested that up
to 1014 cfu/d of lactobacilli and bifidobacteria, a dose far
greater than the usual intake of 109-1011 cfu/d, is acceptable for human consumption(31). Lactobacillus paracasei 33
contained 1 × 109 cfu/g daily for three weeks in this study.
Safety was monitored throughout the trial. At the beginning of weeks 0, 3 and 6, the participants received a physical
examination including inquiries, inspections, height, weight,
measurement of vital signs, and collection of routine clinical
laboratories. All participants were asked about adverse events
during the trial and at follow-up after 6 months by telephone.
VI. Statistical Concerns and Analysis
As this clinical trial was an early phase exploratory study,

Table 2. The influence of regimens on the half time of gastric emptying (Get 1/2) in different age groups
Age

N1

Baseline

Placebo

Lactobacillus

20-40

7

73.0 (16.0)

85.7 (10.5)

87.8 (10.0)

41-60

8

79.1 (23.9)

70.9 (33.1)

68.4 (15.2)

0.580

0.280

0.013*

P values
1

N = number of volunteers.
*P < 0.05.

no formal sample size estimate was performed. Recruitment
would be stopped when the investigators had sufficient information on safety and feasibility, as well as it could make a
judgment about effectiveness or any difference. All statistical
analyses were carried out using repeated-measures analysis
of variance (ANOVA) with SPSS software (SPSS 16, IBM,
Somers, NY). Results were reported as means±SD. If a
significant interaction of regimen and time was documented
(p < 0.05), values at single time points were compared by
one-way ANOVA, followed by t-tests if p values were below
0.05. A corrected two-sided p value of below 0.05 was
defined as a significant difference.

RESULTS
I. Demographics and Baseline Characteristics
The healthy volunteers were adequately distributed
between two age groups: 7 in the 20-40 year range, and 8
in the 41-60 year range (Table 1). There is no specific health
status mentioned. Baseline fasting glucose levels of the
participants were all in normal range, but the average was
slightly higher in 41-60 age group.
II. Gastric Emptying
In the 20-40 age group, the half times of gastric emptying
(GEt1/2) for baseline, placebo, and Lactobacillus regimen
periods were 73.0 ± 16.0, 85.7 ± 10.5 and 87.8 ± 10.0 min,
respectively, while those in the 41-60 age group were 79.1
± 23.9, 70.9 ± 33.1 and 68.4 ± 15.2 min, respectively. There
were relevant differences in gastric emptying for the various
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Discussion

regimen periods (p = 0.013)(Table 2). The influence of regimens on gastric emptying percentage (GEP) in the different
age groups and frames are shown in Table 3. For both age
groups, various positive trends of improvement on GEP were
shown after taking Lactobacillus in all individuals (Figure 1).

The current study demonstrated that taking multiplestrain Lactobacillus products slightly accelerates gastric
emptying in the healthy 41-60-year-old population. Generally, gastric emptying showed slightly with age, and remains
within the normal range in young people(34,35). The magniIII. Body Mass Index (BMI)
tude of the prokinetic response was different in the two age
When the subjects were divided into two groups groups, and the effect appeared more potent in the 41-60-year1635-101.04.23-revised
according to BMI (normal, n = 10 and exceptional,
n = 5) old population. Serious adverse events were not observed in
the results trended toward improved gastric emptying with this study. Although we did not exclude the possibility of a
better response with higher doses and a longer evaluation
Lactobacillus therapy, but this effect did not 1reach
statistical
Figure
1.
significance (p = 0.10)(Figure 2). There was also no evidence time, the current study design seemed adequate on the basis
of any meaningful effect of Lactobacillus or placebo on blood of previously published experience. We used Tc-99m scintigraphy, which is the best-accepted diagnostic measurement for
glucose or BMI.
1635-101.04.23-revised
gastroparesis. In older adults, special care should be taken to
IV. Blood Glucose

It is now well established that fasting blood glucose
levels and acute change in blood glucose concentrations
have a significant reversible effect on gastric emptying(32,33).
Although the values of half time of gastric emptying (GEt1/2)
were shortened with Lactobacillus therapy, there were no
significant differences in fasting blood glucose in either age
group in this pilot study with eligible volunteers (Figure 3).
2
3

V. Safety and Adverse Effects

Calculations of ADI (acceptable daily intake) for
probiotics and NOAEL (no observed adverse effect levels)
showed that the pills contained 1010-1012 cfu/d of Lactobacilli in this study, for which detrimental effects are rare2(31).
No serious adverse events were observed during the admin3
istration period of Lactobacillus and at follow-up after 6
months by telephone. In addition, abdominal symptoms
such as inappetence, diarrhea, constipation, flatulence or
abdominal discomfort were not observed.

Half-time of gastric emptying (minutes)

Figure 1.

1

180.00

Age 20-40

160.00

Age 41-60

140.00
120.00
100.00
80.00
60.00
40.00
20.00
0.00

Baseline

Placebo
Regiments

Lactobacillus

Figure 1. The influence of regimens on half-time of gastric emptying
(GEt1/2) in different age groups. The GEt1/2 of the 20-40 year-old
subjects who took the lactobacillus increased. This indicated that the
lactobacillus regimen does not promote the effect of gastric emptying.
Meanwhile, the GEt1/2 of the 41-60 year-old subjects who took the
lactobacillus decreased. This indicated that the lactic acid bacteria
regimen does endorse the effect of gastric emptying.

Table 3. The influence of regimens on gastric emptying (GEP) in different age groups and frames
Baseline
Frame
72th

Lactobacillus

Placebo
Frame
90th

Frame
72th

Frame
90th

Frame
72th

Frame
90th

49.6 (9.6)

36.6 (9.4)

44.0 (10.3)

49.4 (11.1)

60.4 (13.2)

0.033*

0.020*

Age 20-40
N1
GEP

7
2, 3

49.1 (10.1)

59.0 (10.8)

38.4 (7.0)

Age 41-60
N1
GEP

8
2, 3

P values

43.9 (18.1)

56.3 (17.5)

55.0 (15.0)

63.8 (17.3)

0.507

0.726

0.019*

0.077

30

1

N = Number of volunteers.
2
Values are means (SD)
3
GEP = gastric emptying percentage.
* P < 0.05
30

Figure 2.
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Half-time of gastric emptying (minutes)

1

180.00

Normal

160.00

Abnormal

140.00
120.00
100.00
80.00
60.00
40.00
20.00
0.00

Baseline

Placebo
Regiments

Lactobacillus

Figure 2. The influence of different regimens on gastric emptying
time in normal and abnormal BMI subjects. The current study further
3
divided subjects into the BMI normal group and BMI abnormal group.
In general, BMI less than 20 is underweight, BMI within 20 to 25 is in
635-101.04.23-revised
ideal range, BMI between 26 to 29 is a risk factor to health, and BMI
greater than 30 is a high risk factor to health. In this study, BMI between
20 to 25 were assigned as the BMI normal group, while the others were
igure 3.
assigned as the BMI abnormal group. The results showed that after the
subjects with normal BMI took lactobacillus, their gastric emptying
time did not decrease. However, after the subjects with abnormal BMI
took lactobacillus, their gastric emptying time decreased. Therefore,
1635-101.04.23-revised
for people with abnormal BMI, taking lactobacillus might improve
their gastric emptying function.
2

1

Figure 3.
Age 20-40

120.00

Age 41-60

31

Blood Glucose (mg/dl)

100.00
80.00
60.00
31

40.00
20.00
0.00

2

Baseline

Placebo
Regiments

Lactobacillus

Figure 3. The influence of different regimens on subjects’ blood
glucose level. According to Figure 3, there was no effect of taking the
lactic acid bacteria on the blood glucose level in the 20-40 and 41-60
year-old subjects.

manage pain while optimizing daily function and mobility,
with the fewest adverse medicinal side effects. It suggests
that the low toxicity and the limited number of subjects do not
permit a statistically valid conclusion about safety.
Abundant evidences exist in support of the therapeutic
use of probiotics in several gastrointestinal motility disorders(36). Metabolic products of intestinal bacteria, such as
variant short-chain fatty acids or chemotactic peptides may
stimulate the enteric nervous system and influence the rate
32
of gut transit(37,38). There is also accumulating evidence that

a number of lactic acid bacteria species have in vitro and in
vivo activity against H. pylori(39). Recent studies showed
that probiotic therapy significantly decreased the number of
CD3+ cells in the stomach of previously H. pylori infected
mice compared with placebo-treated mice in parallel with a
faster recovery of gastric emptying(13). Thus, mechanisms to
support probiotics in accelerate gastric emptying are primarily
supposed to be its prokinetic effects of fermentation products
and antibiotic properties which may influence the ecosystem
of gastrointestinal tract(40). Other mechanisms such as direct
modulation of inflammatory and neuroendocrine pathways
by probiotics were also proposed(41). Studies have also
confirmed that probiotic bacteria modulate systemic immune
activity and epithelial function(36), that also contribute to
accelerate gastric emptying. Yet, not all probiotic strains exert
similar therapeutic effects. It is paramount in selection of
potent probiotics species or combination of multiple strains
to achieve synergic effects. The primary motive of this early
stage clinical trial is to set up appropriate protocols to test
the efficacy of capsules containing multiple strains of probiotics in treating gastric motility disorder, especially diabetic
gastroparesis.
Recent studies reported that Lactobacillus reuteri can
significantly accelerate gastric emptying and improve regurgitation in infants(11,29). These studies highlighted that some
specific species of lactic acid bacteria can accelerate gastric
emptying in special age groups. In a recent animal study, the
rate of charcoal transit was significantly higher in probiotic
dahi-fed animals than in diabetic control groups(42). Previous
epidemiological studies showed that metabolic syndrome is
prevalent and increases with age, especially above 40 years
old(43). In our present study, the positive effect in 41-60
year-old participants who are prone to metabolic syndrome
is compatible to our hypothesis and previous animal studies.
Blood glucose levels were not formally evaluated daily,
but instead measured a total of 3 times. A significant difference in BMI or blood glucose after placebo or Lactobacillus
regimens was not observed. Previous studies showed that
changes in blood glucose concentration might have a major
effect on gastric emptying, especially when studies include
healthy subjects and patients with diabetes; gastric emptying
is slower during hyperglycaemic episodes than during euglycaemia(21). However, the acceleration of gastric emptying
has no effect on overall glycaemic control, the magnitude
of glucose excursions and hypoglycaemic episodes(44-47).
However, the acceleration of gastric emptying by Lactobacillus regimen reduces dyspeptic symptoms, no effect on
glycaemic control, in healthy human volunteers. These results
indicated that BMI and blood glucose may not be influenced
by Lactobacillus ingestion, especially on a short-term basis.
For early phase exploratory clinical trial(48,49), this study
was not designed to comment the efficacy(50,51) of the lactobacillus treatments on gastric emptying but explore whether
there are differences on different age groups. In fact, the data
analysis showed that the mean difference in subjects’ GEt1/2
of week 0, 3 and 6 in the 20-40 age group were between ±
15 minutes; the 41-60 age group were between ± 11 minutes.
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Thus, efficacy cannot be concluded in each age group by this
small number trial. The duration of the study may be also
considered too short. Overall clinical advantage of lactobacillus treatments was not significant enough in this study, but
it was associated with deferent benefit in 41-60 age group
which can be a specific group to investigate in phase II or III
trial. Another limitation is placebo effects which was widely
accepted as a common problem in clinical trials of gastrointestinal diseases(52). All volunteers had been informed of the
purpose, which may potentiate the subject-expectancy effect.
In Table 3, improvement on gastric emptying percentage was
shown to be significant in the placebo period of both the 20-40
age group and 41-60 age group (p = 0.019). Several factors
are thought to contribute towards the placebo effect including
Pavlovian conditioning, beliefs outcome and the expectation
of a positive outcome. Our study was limited in that it was a
short trial designed to investigate differences among healthy
individuals of the effects of Lactobacillus ingestion on gastric
emptying. Thus, the present report can be regarded as a pilot
study that should be verified in further clinical trials.
Future studies are required to establish clinical characteristics as predictors of a better response to Lactobacillus,
compared to placebo or pharmaceutical agents. In addition,
studies specifically designed to assess dosing requirements
and efficacy are needed. If the low number of adverse events
seen in this study remains the same in a large, randomized
clinical trial, Lactobacillus might come to be considered safe
for GI motility intervention in healthy individuals. To the best
of our knowledge, this study is the first clinical trial in Taiwan
investigating the effects of probiotics on gastric emptying.
It provides several useful contributions to the field. First, it
is a confirmation that a regimen with capsules containing
multiple strains of Lactobacillus is safe and well tolerated.
Second, it is a demonstration or modeling of trial procedures
for subsequent trials of probiotic products for gastroparesis
regimens in Taiwan. Third, it is an establishment of the basis
for subsequent studies designed to demonstrate that probiotics are capable of accelerating gastric emptying in gastroparesis patients, including those with functional dyspepsia, DM
gastroparesis and a variety of different etiologies.
Identification of specific subgroups that might represent
an ideal target population is an important goal for future
clinical trials assessing putative Lactobacillus therapeutic
agents, particularly in populations having a higher likelihood of developing gastric dysfunction, or in gastroparesis
patients. In conclusion, this early stage trial indicated that
the multi-strain Lactobacillus capsule is safe and our results
provided some evidence that it showed beneficial effects on
gastric emptying in healthy adults above 40 years of age. This
probiotic preparation may become a therapeutic approach in
future trials for pathological gastric emptying delay, by implication, especially in diabetic gastroparesis.
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